Migraine & Headache News Archive
The use of the HEADWORK questionnaire may provide insight into the effects of migraines on work productivity and lost workdays.
Approximately half of patients with migraine have kinesiophobia, and the condition is associated with greater severity, not presence of cutaneous allodynia.
In a retrospective analysis, investigators assessed the effects of topical trigger point treatments on headache symptoms in patients with migraine.
Researchers showed high migraine induction capabilities with calcitonin gene-related peptide (CGRP) in people with migraine who responded to erenumab treatment compared to data from previous CGRP provocation experiments.
Higher levels of serum 25-hydroxyvitamin D may be associated with lower risk for migraine headaches.
Migraine may be associated with self-reported attention deficit and hyperactivity disorder symptoms in university students.
Erenumab 140 mg is a well-tolerated and potentially effective preventive treatment for patients with episodic migraine, according to a phase 3b study.
Study showed no evidence for an effect of achievement motivation on the frequency of acute headache medication use.
Genetic risk scores that focus on 2 single-nucleotide polymorphisms associated with migraines without aura might help predict patient response to triptan treatment.
There is a need for a tool in primary care to aid in managing and diagnosing headache disorders.
Counseling practices and headache management indicate the need for training and education of pharmacists in an Ethiopian city to better serve individuals with headache complaints.
The NDA submission included data from two Phase 3 trials, SAMURAI and SPARTAN.
A study looked at use of IV fluids, ketorolac, dexamethasone, and DRAs prochlorperazine/metoclopramide from 1999-2000 to 2014 in the treatment of patients with migraine admitted to the ED.
Improved pain acceptance may be associated with a decrease in headache-related disability in patients with migraine.
Distinct response patterns of the 22-item Sino-Nasal Outcome Test may be used to distinguish nonsinogenic headaches from chronic rhinosinusitis.
Investigators examined the link between migraine and attention-deficit/hyperactivity disorder.
Investigators examined opioid prescribing trends in children and adolescents with primary headaches during ambulatory and emergency department visits.
The authors built a customized structured clinical documentation support toolkit that collects hundreds of fields of discrete, standardized data.
Investigators aim to develop a non-invasive treatment for medically refractory chronic migraine not requiring a permanent implant.
Investigators identify subgroups of individuals with migraine based on comorbidities and concomitant condition.
Many headache smartphone applications or "apps" share information with third parties, more than half of which have privacy policies stating that the shared data will be used to serve targeted advertisements from third parties.
Investigators examine most bothersome headache-associated symptoms as a feasible alternative to using 4 c-primary end points in acute migraine treatment trials.
Researchers sought to assess the prevalence of concomitant prescribing of opioid analgesics with a triptan or a serotogeneric antidepressant in individuals with migraine.
The Sapphire has a rechargeable and reloadable fill capacity; it can be activated monthly by inputting a unique, prescription-only authorization code, delivered via a radio-frequency identification card that is mailed to the patient.
Patients with migraine headaches—particularly those accompanied by aura—may be at significantly increased risk for 30-day hospital readmission because of pain after surgery.
Investigators examined rates, predictors, and outcomes of neuroimaging in pediatric and adolescent patients who presented to the ED with a headache.
Investigators assessed the effect of erenumab on total exercise time, time to exercise-induced angina, and ST depression in patients with stable angina.
No significant clinical differences have been found between individuals with cluster headache who experience aura vs no aura.
Investigators examined the effect of onabotulinumtoxinA on aura frequency and severity in patients with hemiplegic migraine.
Investigators examined the efficacy of oral steroids and greater occipital nerve injections as transitional therapies for cluster headache management.
The location of migraine pain may not be associated with psychiatric distress, emergency department visits, or healthcare use.
Known risk factors for medication overuse headache include smoking, anxiety, family history of substance abuse, migraine history, depression, and obsessive-compulsive disorder.
Carefully assessing cognitive performance using a screening test to detect visuospatial/executive, attention, and memory dysfunction in patients with migraine.
The odds of first-line treatment success in pediatric migraine may be lower in patients who have higher baseline headache frequency and medication overuse headache.
For many patients with refractory headache, ketamine treatment may provide short-term analgesia with tolerable adverse events.
Two-thirds of parents report that their child has had a headache not related to a fall or head injury.
Men with migraines were found to have increased levels of estradiol and to be more likely to have relative androgen deficiency compared with men without migraines.
This Phase III, multicenter, double-blind study sought to explore the effect of fremanezumab on the potential reversion from chronic migraine to episodic migraine.
The comorbidities commonly reported in patients with migraine include those involving cardiovascular, psychiatric, pain, and respiratory conditions, the researchers reported.
Patients with difficult-to-treat migraine were randomly assigned 1:1 to either 140 mg erenumab or placebo.
Rimegepant is a safe and efficacious pharmacological treatment of acute migraine in adults.
OnabotulinumtoxinA at 195 UI may be effective in reducing the number of headaches per month and medication intake in patients with chronic migraine and medication overuse.
Approximately half of patients who were referred for behavioral treatment for migraine were found to initiate treatment.
A phase 3 study examined a low-dose subcutaneous autoinjection of sumatriptan in the acute treatment of migraines with or without aura in adults.
Dr Richard Lipton and Dr Paul Martin debated the pros and cons of trigger avoidance in patients with migraine headache at the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California.
The risk for cochlear disorders — particularly tinnitus — may be higher in individuals with a history of migraine.
In their interim analysis of a 5-year open-label extension trial, study investigators evaluated the safety and tolerability of erenumab treatment in episodic migraine patients who completed ≥3 years of the trial or discontinued treatment.
The CaMEO study is a prospective, longitudinal web-based survey designed to characterize the impact of migraine on aspects of quality of life.
The 2 randomized, phase 3, double-blind studies included in this presentation were the SAMURAI and SPARTAN trials.
Individuals with chronic migraine may present with age-related changes in cortical thickness.
The investigators assessed participants for photophobia, unilateral location, phonophobia, exacerbation, nausea, pulsatility, sensory aura, pain level and frequency, visual aura, and allodynia features.
Color-selective photophobia was found to be more prevalent during the ictal vs interictal phase in individuals with migraine.
DFN-02 nasal spray may be effective, well tolerated, and safe for the acute treatment of episodic migraine.
Results from the ACHIEVE II study were presented at the American Headache Society's 60th Annual Scientific Meeting.
Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.
Eptinezumab has shown 100% bioavailability when administered intravenously.
The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.
In the post-hoc analysis, researchers evaluated the time to onset of effect of galcanezumab as well as whether treatment with the study drug was associated with a reduction in migraine headache days.
This cross-sectional, observational study sought to evaluate the accuracy of individuals with headache to appraise the relationship between potential trigger factors and headache events.
More patients in the 100 mg and 300 mg eptinezumab groups achieved a 100% reduction in monthly migraine days over the 112 weeks compared with placebo.
This randomized, open-label study examined participant reported outcomes, safety, and tolerability of onabotulinumtoxinA and topiramate in adults with chronic migraines.
Fremanezumab has shown efficacy in safely reducing monthly headache days in individuals with chronic migraine.
This retrospective study sought to assess migraine patterns in 69 menopausal women between ages 40 and 60 who were treated at Partners Healthcare Hospitals for concurrent migraine headache.
Transcutaneous electrical nerve stimulation may represent an effective treatment for the prevention and management of migraine.
The use of transnasal sphenopalatine ganglion block is safe and effective for providing short-term relief from acute migraine headaches.
Polypharmacy in individuals with primary headache may arise out of a prescribing cascade.
Clinical evidence supports a strong relationship between cephalalgic migraine and allergic rhinitis in children.
Investigators examined baseline and 1-year variables and their association with quality of sleep in chronic tension-type headaches.
A high percentage of cannabis users take the drug to treat headache and probable migraine.
Medication overuse headache may be a significant disease burden in the general population.
Investigators collected audio recording of physician-patient interaction during office visits to evaluate communication patterns.
Investigators sought to determine the association between smoking and headache.
This study sought to further examine the association between migraine and subclinical hypothyroidism.
Investigators examined the cranial autonomic nervous system in patients with migraine by applying the cold pressor test.
Investigators examined presenting features of migraine vs arterial ischemic stroke in children presenting to the emergency department.
Patients with migraine may exhibit higher prevalence of restless leg syndrome, fibromyalgia, and depressive symptoms compared with individuals not experiencing migraines.
The antiepileptic drug levetiracetam may represent an effective prophylactic treatment option for episodic migraine.
Lower work ability in patients with chronic migraine may be associated with high quantitative and emotional demand.
Manual trigger point treatments of head and neck muscles may be associated with reductions in the duration, frequency, and intensity of tension-type headache and migraine headache attacks.
Investigators aimed to find the link between exposure to triptans in utero and externalizing behavior, internalizing behavior, communication, and temperament in children.
In patients with comorbid insomnia and chronic migraine, a cognitive behavioral treatment of insomnia may effectively reduce headache frequency.
Investigators examined remission rates and predictors of remission in patients with chronic headache over 11 years.
Neck pain is a symptom of migraine only, not the result of an underlying muscle dysfunction that triggers migraine attacks.
Investigators examined the characteristics of visual symptoms during migraine attacks in children and adolescents.
Investigators examine the safety and efficacy of intravenous aminophylline for postdural puncture headaches.
The first-in-class migraine prevention drug will be available to patients within 1 week of the approval.
Investigators conducted a prospective cohort study to examine the risk of incident hypertension in women with migraine.
The Neck Disability Index, and to a lesser extent, the Numeric Pain Rating Scale, may represent reliable measures for patients to self-report cervicogenic headache-associated disability and pain in the short-term.
Migraine headache is associated with a higher risk for major adverse cardiovascular and cerebrovascular events.
The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.
Patients with chronic migraine exposed to visual stimulation may have enhanced activity in the spinal trigeminal nucleus and the right superior colliculus compared with healthy individuals.
The frequency of migraine and sarcoidosis comorbidity was examined in a cohort study.
The effect of aerobic exercise in reducing migraine-associated burden in individuals with comorbid tension-type headache and neck pain may not be mediated by an effect on nociceptive pathways.
Compared to placebo, selective serotonin reuptake inhibitors (SSRIs) were associated with a significantly higher risk of headache (risk ratio [RR] 1.06, 95% CI: 1.00 to 1.13; P =.045).
Aerobic exercise may improve migraine frequency, intensity of pain, and the duration of tension-type headache.
Repeated injections of nerve growth factor may lead to increased mechanical sensitivity in the masseter — but not in the temporalis muscle — as well as increased entropy.
A period of observation after an educational session may be important to confirm medication-overuse headache (MOH) diagnoses.
Researchers aim to determine a pattern of migraine, in terms of frequency, intensity, and analgesic use, in women with and without menstrual migraine.
Eptinezumab, a humanized monoclonal antibody specific to calcitonin gene-related peptide, may be an effective prophylactic for individuals with frequent episodic migraines.
Treating chronic migraine with onabotulinumtoxinA may reduce the number of headache days when administered according to the National Institute for Health and Care Excellence guidelines.
Clinical Pain Advisor Articles
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- IASP Updates Classification of Chronic Pain
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Pulsed Ultrasound May Be Effective for the Treatment of Rib Fractures
- CDC: Top 10 Drugs Involved in Drug Overdose Deaths
- Chronic Secondary Headache or Orofacial Pain IASP Classification
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Case Study: Fever and Headache in an Adolescent Boy
- Racial Disparities May Have Widened After Hospital Readmissions Reduction Program Implementation
- Cervical Dysfunction Needs Clarification to Identify Link With Headache